Utah Administrative Code
Topic - Health
Title R438 - Utah Public Health Laboratory
Rule R438-15 - Newborn Screening
Section R438-15-4 - Implementation

Universal Citation: UT Admin Code R 438-15-4

Current through Bulletin 2024-06, March 15, 2024

(1) The health care provider shall submit a sample for each newborn in the state to the newborn screening testing, except as provided in Section R438-15-12.

(2) The Department, after consulting with the Newborn Screening Advisory Committee, will determine the disorders on the Newborn Screening Panel, based on demonstrated effectiveness and available funding. Disorders for which the laboratory screens the infant blood are:

(a) biotinidase deficiency;

(b) congenital adrenal hyperplasia;

(c) congenital hypothyroidism;

(d) galactosemia;

(e) hemoglobinopathy;

(f) amino acid metabolism disorders:
(i) phenylketonuria;

(ii) tyrosinemia type 1;

(iii) tyrosinemia type 2;

(iv) tyrosinemia type 3;

(v) maple syrup urine disease;

(vi) homocystinuria;

(vii) citrullinemia;

(viii) argininosuccinic aciduria;

(ix) argininemia;

(x) hyperprolinemia type 2;

(g) fatty acid oxidation disorders:
(i) medium chain acyl coA dehydrogenase deficiency;

(ii) very long chain acyl coA dehydrogenase deficiency;

(iii) short chain acyl coA dehydrogenase deficiency;

(iv) long chain 3-OH acyl coA dehydrogenase deficiency;

(v) short chain 3-OH acyl coA dehydrogenase deficiency;

(vi) primary carnitine deficiency;

(vii) carnitine palmitoyl transferase 1 deficiency;

(viii) carnitine palmitoyl transferase 2 deficiency;

(ix) carnitine acylcarnitine translocase deficiency;

(x) multiple acyl coA dehydrogenase deficiency;

(h) organic acids disorders:
(i) propionic acidemia;

(ii) methylmalonic academia;

(iii) malonic aciduria;

(iv) isovaleric acidemia;

(v) 2-methylbutyryl coA dehydrogenase deficiency;

(vi) isobutyryl coA dehydrogenase deficiency;

(vii) 2-methyl-3 -OH-butyryl-coA dehydrogenase deficiency;

(viii) glutaric acidemia type 1;

(ix) 3-methylcrotonyl coA carboxylase deficiency;

(x) 3-ketothiolase deficiency;

(xi) 3-hydroxy-3 -methyl glutaryl coA lyase deficiency;

(xii) holocarboxylase synthase deficiency;

(i) cystic fibrosis;

(j) severe combined immunodeficiency syndrome;

(k) disorders of creatine metabolism;

(l) spinal muscular atrophy;

(m) x-linked adrenoleukodystrophy;

(n) pompe disease; and

(o) mucopolysaccharidosis type I.

Disclaimer: These regulations may not be the most recent version. Utah may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.